Showing results (11-20 of 22) with videos related to
Sort By:
Pageof 3
Cell Reports|August 4, 2024
Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1Alexander Muik, Jasmin Quandt, Bonny Gaby Lui, et al.Oncotarget|April 19, 2017
Unique properties of thymic antigen-presenting cells promote epigenetic imprinting of alloantigen-specific regulatory T cellsGarima Garg, Eirini Nikolouli, Matthias Hardtke-Wolenski, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 20, 2013
Active demethylation of the Foxp3 locus leads to the generation of stable regulatory T cells within the thymusAras Toker, Dirk Engelbert, Garima Garg, et al.Oncoimmunology|November 20, 2019
Tumor cell expression of B7-H4 correlates with higher frequencies of tumor-infiltrating APCs and higher CXCL17 expression in human epithelial ovarian cancerHeather L MacGregor, Carlos Garcia-Batres, Azin Sayad, et al.Cell Reports|August 1, 2023
Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunityAlexander Muik, Bonny Gaby Lui, Jasmin Quandt, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2018
Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in MelanomaAras Toker, Linh T Nguyen, Simone C Stone, et al.Oncoimmunology|February 21, 2022
An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulationAlexander Muik, Isil Altintas, Friederike Gieseke, et al.Journal for Immunotherapy of Cancer|June 10, 2022
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activityAlexander Muik, Homer C Adams 3rd, Friederike Gieseke, et al.Scientific Reports|July 24, 2025
A hexamerization-enhanced, Fc-silenced agonistic CD27 antibody amplifies T-cell effector functions as single agent and in combination with PD-1 blockadeIşıl Altıntaş, Kristina B Nürmberger, Andrea Imle, et al.Journal for Immunotherapy of Cancer|April 11, 2025
Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effectsMichela Capello, Angelica Sette, Theo Plantinga, et al.Pageof 3